Earnings● Neutral

$BIIB Q1 Earnings Hit by $34M in R&D Charges

April 6, 2026 at 12:54 PMBy AlphaScalaEditorial standards

Click a ticker for a live chart

Biogen expects a $0.19 per share reduction in net income from R&D costs. With an Alpha Score of 54, investors should watch the April 30 formal earnings release.

Continue with

Stocks

Biogen Lupus Drug Hits Phase 3 Goal, Opens New Pipeline Path

Trading Q&A

How to start trading stocks as a beginner?

AlphaScala Research Snapshot

Live stock context for companies directly referenced in this story

Methodology Portfolios

Biogen Inc.BIIBHealthcare

Alpha Score of 54 reflects moderate overall profile with strong momentum, weak value, weak quality, moderate sentiment.

Full stock page Alpha Score Public portfolios

Alpha Score

Weak

This panel uses AlphaScala-native stock data — proprietary scoring and live snapshots.

Biogen has issued a preliminary warning regarding its first-quarter financial results, citing an expected negative impact on net income. The biotechnology company projects a reduction of approximately $0.19 per share due to in-process research and development (IPR&D) charges totaling roughly $34 million. These adjustments are being disclosed ahead of the company’s formal first-quarter earnings report, which is scheduled for release on April 30.

How this story was producedLast reviewed Apr 6, 2026

Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.

Editorial Policy·Report a correction·Risk Disclaimer

$BIIB Q1 Earnings Hit by $34M in R&D Charges

Explore More

More from AlphaScala

Trading Q&A

Related Tools & Research